000277997 001__ 277997
000277997 005__ 20250504001149.0
000277997 0247_ $$2doi$$a10.1177/13872877251319468
000277997 0247_ $$2pmid$$apmid:40095481
000277997 0247_ $$2ISSN$$a1387-2877
000277997 0247_ $$2ISSN$$a1875-8908
000277997 0247_ $$2altmetric$$aaltmetric:175381687
000277997 037__ $$aDZNE-2025-00524
000277997 041__ $$aEnglish
000277997 082__ $$a610
000277997 1001_ $$0P:(DE-2719)9000482$$aBecker, Cornelia$$b0
000277997 245__ $$aDementia diagnosis and prescription of antidementia drugs: An analysis of German claims data (2006-2016).
000277997 260__ $$aAmsterdam$$bIOS Press$$c2025
000277997 3367_ $$2DRIVER$$aarticle
000277997 3367_ $$2DataCite$$aOutput Types/Journal article
000277997 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745920333_15704
000277997 3367_ $$2BibTeX$$aARTICLE
000277997 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277997 3367_ $$00$$2EndNote$$aJournal Article
000277997 520__ $$aBackgroundUse of claims data allows to analyze health service characteristics of dementia, which is one of the most frequent cognitive disorders in Germany and worldwide.ObjectiveThe study aimed at describing the variability in dementia diagnoses and in antidementia drug prescription pattern.MethodsWe analyzed data from a population-based sample of one of the largest German statutory health insurances. The cohort included 30,403 patients with incident dementia diagnosis from 2006-2016. We described frequencies, patterns, and interrelations of diagnoses (Alzheimer's disease (AD), vascular dementia, other specific dementia, unspecified dementia (UD), antidementia drugs (ADD), and professional groups. We described switches in diagnostic and medication patterns between index quarter and following quarters, and evaluated the prescriptions in relation to national guidelines.ResultsA total of 87% of patients received a diagnosis of UD in at least one quarter of insurance. In the quarter of incident diagnosis, 14% of patients received more than one diagnostic code of dementia, whereas over the course of observation, the majority of patients received more than one diagnostic code (61%). Most patients were diagnosed by a general practitioner without involving a specialist. All professional groups primarily made UD diagnoses except specialists who mainly diagnosed AD. Thirty-five percent of all patients and 67% of AD patients were prescribed an ADD at least once.ConclusionsSpecialists made the most specific diagnoses and prescribed most ADDs. A specialist consultation may be advisable, but only 34% of patients visited one. Many AD patients might be left untreated due to underdiagnosis or -treatment.
000277997 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000277997 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277997 650_7 $$2Other$$aAlzheimer's disease
000277997 650_7 $$2Other$$aaged
000277997 650_7 $$2Other$$adrugs
000277997 650_7 $$2Other$$aepidemiology
000277997 650_7 $$2Other$$ageneral practice
000277997 650_7 $$2NLM Chemicals$$aNootropic Agents
000277997 650_2 $$2MeSH$$aHumans
000277997 650_2 $$2MeSH$$aGermany: epidemiology
000277997 650_2 $$2MeSH$$aDementia: diagnosis
000277997 650_2 $$2MeSH$$aDementia: drug therapy
000277997 650_2 $$2MeSH$$aDementia: epidemiology
000277997 650_2 $$2MeSH$$aMale
000277997 650_2 $$2MeSH$$aFemale
000277997 650_2 $$2MeSH$$aAged
000277997 650_2 $$2MeSH$$aAged, 80 and over
000277997 650_2 $$2MeSH$$aNootropic Agents: therapeutic use
000277997 650_2 $$2MeSH$$aDrug Prescriptions: statistics & numerical data
000277997 650_2 $$2MeSH$$aMiddle Aged
000277997 650_2 $$2MeSH$$aCohort Studies
000277997 650_2 $$2MeSH$$aPractice Patterns, Physicians': statistics & numerical data
000277997 650_2 $$2MeSH$$aInsurance Claim Review
000277997 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000277997 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000277997 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000277997 7001_ $$00009-0001-5654-9161$$aHerschung, Lucas$$b1
000277997 7001_ $$0P:(DE-2719)2811376$$aGomm, Willy$$b2
000277997 7001_ $$0P:(DE-2719)2810511$$aHaenisch, Britta$$b3$$eLast author
000277997 773__ $$0PERI:(DE-600)2070772-1$$a10.1177/13872877251319468$$gVol. 104, no. 3, p. 698 - 708$$n3$$p698 - 708$$tJournal of Alzheimer's disease$$v104$$x1387-2877$$y2025
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524%20SUP.docx
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524.pdf$$yOpenAccess
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524%20SUP.doc
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524%20SUP.odt
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524%20SUP.pdf
000277997 8564_ $$uhttps://pub.dzne.de/record/277997/files/DZNE-2025-00524.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000277997 909CO $$ooai:pub.dzne.de:277997$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000277997 9101_ $$0I:(DE-588)1065079516$$60009-0001-5654-9161$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000277997 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811376$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000277997 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810511$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000277997 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000277997 9141_ $$y2025
000277997 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000277997 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000277997 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000277997 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000277997 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000277997 9201_ $$0I:(DE-2719)1013010$$kAG Hänisch$$lPharmacoepidemiology$$x0
000277997 980__ $$ajournal
000277997 980__ $$aVDB
000277997 980__ $$aUNRESTRICTED
000277997 980__ $$aI:(DE-2719)1013010
000277997 9801_ $$aFullTexts